[Study on the cost-effectiveness, benefit and utility analysis on the infant inoculation hepatitis B vaccine in Shanghai].
OBJECTIVE
To study the cost-effectiveness, benefit and utility of infant hepatitis B vaccination in Shanghai from 1992 to 2001.


METHODS
To calculate the cost of hepatitis B vaccination by cost analysis method. Both the numbers of persons with HBsAg positive and patient with hepatitis B, cirrhosis and liver cancer decreased as the index of direct effect. To study the sick-time and the cost of treating hepatitis B, cirrhosis and liver cancer patients, a face to face questionnaire was used and quasi method was adopted to understand the effect of cure and the course of hepatitis B. The cost benefit analysis method was also used to calculate the cost benefit of HBV vaccine. The disability adjusted life years (DALY) was regarded as an index of utility to measure the disease burden.


RESULTS
Input of 501,129.49 Yuan might have the result of reducing one liver cancer patient, ten cirrhosis patients, one hundred chronic hepatitis B patients and one thousand HBsAg positive people. The cost of hepatitis B vaccination was 0.24 hundred million Yuan during the past ten years in Shanghai, which had obtained the total benefit value of 41.22 hundred million Yuan, with a cost benefit ratio of 1:172 Yuan. It was estimated that the total disease burden of hepatitis B, cirrhosis and liver cancer patients was 59,762.55 DALY in order to reduce one DALY loss cost of 402.50 Yuan.


CONCLUSIONS
HBV vaccine inoculation in infants seemed to be a low-cost input and high-effect output strategy.
Wu
Gui-Ying
GY
Department of Health Statistics of Social Medicine, School of Public Health, Fudan University, Shanghai 200032, China.
Gong
You-Long
YL
Yu
Shu-Li
SL
Shao
Rui-Tai
RT
Qin
Huai-Jin
HJ
D000328:Adult; D003362:Cost-Benefit Analysis; D005260:Female; D006509:Hepatitis B / Q000150:complications / Q000191:economics* / Q000517:prevention & control*; D017325:Hepatitis B Vaccines / Q000191:economics / Q000627:therapeutic use*; D006801:Humans; D017589:Immunization Programs / Q000191:economics*; D007231:Infant, Newborn; D008103:Liver Cirrhosis / Q000191:economics / Q000209:etiology; D008113:Liver Neoplasms / Q000191:economics / Q000209:etiology; D008297:Male; D008390:Markov Chains; D009313:National Health Programs; D011788:Quality of Life; D011795:Surveys and Questionnaires; D014611:Vaccination
D017325:Hepatitis B Vaccines